Rare Liver Cancer Traps T Cells at the Tumor Edge, and an Old Drug Opens a Narrow Path for Immunotherapy

For many cancers, the key to immunotherapy is not making the immune system angrier, but getting it to where it needs to be. The difficulty in fibrolamellar hepatocellular carcinoma lies precisely in this distance: T cells are not entirely absent, but they are directed away from the tumor core, like a rescue team trapped outside the door. Research by teams including Cornell University and Washington University shows that a drug already approved by the U.S. FDA, called AMD3100, may help bring these T cells back to the battlefield.

Fibrolamellar hepatocellular carcinoma is a rare and aggressive liver cancer that mainly affects children and young adults, accounting for at most about 2% of liver cancer cases. The disease is often already metastatic when detected, and treatment options are limited. Even though immune checkpoint inhibitors have reshaped the treatment landscape for multiple cancers in recent years, their effect on this tumor remains unsatisfactory.

A study published in *Gastroenterology* focused on the tumor microenvironment. Using single-nucleus transcriptomic analysis to observe gene activity in different cells within tumor tissue, the team found that the “fibrous” bands referenced in the name fibrolamellar hepatocellular carcinoma are not merely structural features. The study indicates that hepatic stellate cells altered by cancer produce fibrous proteins, forming thick fibrous bands within the tumor; at the same time, they release signals that guide nearby T cells toward fibrous areas rather than the core where cancer cells are located.

This phenomenon is known as T-cell exclusion. Immune checkpoint inhibitors are designed to release the brakes on T cells and allow them to attack tumors; but if T cells are spatially isolated in the wrong place, simply pressing the accelerator may still not make them hit the target. This may explain why fibrolamellar hepatocellular carcinoma has a limited response to this type of immunotherapy.

The researchers then tested AMD3100 on patient-derived tumor slices. According to a research statement released by Cornell, AMD3100 can block signals related to T-cell migration, allowing T cells to enter the tumor core; when further combined with immune checkpoint inhibition, T-cell activation becomes more pronounced and tumor cell death also increases significantly. These results remain experimental evidence at the tissue-slice level and are not equivalent to proof that the approach is effective in patients.

The appeal of AMD3100 is that it is not a completely new and unknown molecule, but a drug with an existing FDA-approved use, which may reduce uncertainty in early clinical translation. However, clinical trials for rare cancers have always been constrained by patient numbers, disease heterogeneity, and the difficulty of trial design; the research team is still seeking collaboration with liver cancer clinical experts to advance human trials. For now, the significance of this work is not that it announces the arrival of a therapy, but that it turns one reason immunotherapy fails from a vague “nonresponse” into a testable and intervenable biological mechanism.